---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-002855"
form_type: "8-K"
ticker: "SENS"
cik: "0001616543"
company_name: "Senseonics Holdings, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:23:43.827749+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Senseonics reports preliminary 2024 revenue of $22.5M, patient base up 56%, cancels reverse stock split meeting

## Summary
- Preliminary Q4 revenue ~$8.3M; full year 2024 revenue ~$22.5M.
- Patient base grew 56% to ~6,000 global patients; over 1,000 US prescribers in 2024.
- December new patient shipments ~600, highest monthly total; DTC leads doubled in Q4.
- Cash, equivalents, restricted cash ~$74.9M at Dec 31, 2024; operating expenses guided.
- Cancelled special meeting for reverse stock split after share price appreciation; proxies favored split.

## SEC filing metadata
- accession: 0001104659-25-002855
- form_type: 8-K
- ticker: SENS
- cik: 0001616543
- company_name: Senseonics Holdings, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1616543/000110465925002855/0001104659-25-002855-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1616543/000110465925002855/tm252718d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-002855
- JSON: https://secwatch.observer/filing/0001104659-25-002855.json
- Plain text: https://secwatch.observer/filing/0001104659-25-002855.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.